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Background: Women diagnosed with early stage (I or II) breast cancer face a highly challenging decision – whether or
not to undergo adjuvant chemotherapy. We developed a decision quality instrument for chemotherapy for early stage
breast cancer and sought to evaluate its performance.
Methods: Cross-sectional, mailed survey of recent breast cancer survivors, providers, and healthy controls and a retest
survey of survivors. The decision quality instrument includes questions on knowledge and personal goals. It results in a
knowledge score and concordance score, which reflects the percentage of patients who received treatments that
match their goals. Hypotheses related to acceptability, feasibility, validity, and reliability of the survey instrument were
examined.
Results: Responses were received from 352 patients, 89 providers and 35 healthy controls. The decision quality
instrument was feasible to implement with few missing data. The knowledge scores had good retest reliability
(intraclass correlation coefficient (ICC) =0.75). Knowledge scores discriminated between providers and patients (mean
difference 31.1%, 95% CI 26.9, 35.3) and between patients and healthy controls (mean difference 11.2, 95% CI 5.4, 17.1).
Most providers reported that the knowledge items covered essential content. Two of the five goal items had a ceiling
effect, and one goal had low content validity. The goal items had moderate retest reliability (ICC’s 0.57 to 0.78). In the
multivariable model of treatment, none of the patient goals was associated with receipt of chemotherapy. Age and
hormone receptor status were the only variables independently associated with chemotherapy. Most patients (77.6%)
had treatment concordant with that predicted by the model. Patients who had concordant treatment had similar
levels of confidence and regret as those who did not.
Conclusions: The Decision Quality Instrument is a reliable and valid measure of patient knowledge about
chemotherapy, but its ability to measure concordance with patient goals is limited. In this sample, patient goals were
not associated with treatment, and most patients reported they were not asked their preference, suggesting that goals
were not adequately considered in decision making.
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Women diagnosed with early stage (I or II) breast cancer
face a highly challenging decision – whether or not to
undergo adjuvant chemotherapy. Chemotherapy can
provide gains in survival after breast cancer, but it also
poses risks of serious toxicity. Because of this tradeoff
between survival gains and toxicity risks, clinical guide-
lines leave the decision about chemotherapy open to the
patient and provider, for most patients with stage I dis-
ease [1,2]. For Stage I patients, five year survival is quite
high, and chemotherapy has a small absolute impact on
10-year survival [3-5]. Thus, the decision about chemo-
therapy for such patients is a “preference sensitive” one,
for which medical evidence is necessary but not suffi-
cient, and the right choice depends heavily on the pa-
tient’s personal preferences [6]. For patients with stage II
disease, guidelines clearly recommend chemotherapy [1].
For those patients, the decision about chemotherapy
should be an informed one, for which the patient fully
understands the risks and benefits of the treatment.
Breast cancer patients report challenges and dissatis-
faction in making decisions about their treatment [7],
and some patients have significant gaps in knowledge or
unrealistic expectations of the benefits of systemic ther-
apy [8-12]. Patients tend to rely heavily on provider rec-
ommendations about chemotherapy [13], but providers
do not always know or elicit patients’ preferences [14]
and they may convey information in ways that patients
do not understand [15]. Overall, the evidence suggests
that early-stage patients may not be meeting acceptable
standards for informed consent when making decisions
with their providers about adjuvant chemotherapy.
Reducing the rate of uninformed or preference-
insensitive chemotherapy decisions will require better
measures of decision quality, due to a lack of reliable
measures in these domains. A recent international con-
sensus process has defined decision quality as the extent
to which patients are informed and receive treatments
that match their goals [6]. Valid measures of patient
knowledge and preferences for breast cancer chemother-
apy decisions, however, are lacking. Most studies of pa-
tient preferences have focused on the minimum survival
gain that patients require to accept chemotherapy and
have not examined the full set of goals and concerns that
patients express, including risks of complications and
side effects [8,16-19]. Studies of knowledge have relied
on ad hoc measures [8].
To address the need for better assessment of quality in
chemotherapy decisions, we developed a survey instru-
ment to measure patient knowledge and preferences
about chemotherapy for early stage breast cancer, and
evaluated its psychometric properties in a field test in
breast cancer survivors. The instrument results in two
scores, a knowledge score, indicating the extent to whichpatients are informed, and a concordance score, indicat-
ing the percentage of patients who received treatments
that matched their goals. To compare the instrument’s
performance in groups with different levels of know-
ledge, we also surveyed breast cancer providers and
healthy volunteers. The purpose of the field test was to
evaluate feasibility, validity, and reliability of a new in-
strument that has never been used with breast cancer
patients. Given the stress and vulnerability of newly di-
agnosed patients, we decided to conduct the field test
with patients who had recovered from treatment. This
approach would provide sufficient data to determine
whether the questions were performing as intended,
identify problematic wording or other issues, and allow
some freedom to include more items than might be rea-
sonably asked of newly diagnosed patients.
Methods
Initial instrument development
The approach to measuring decision quality draws from
normative and behavioral decision making theories and
is based on the conceptual framework of shared decision
making, as described by Mulley [20] and extended by
Mulley and Sepucha [21]. Decision quality is defined as
the extent to which patients are informed and receive
treatments that match their goals [6]. Thus the two pri-
mary domains of the instruments are knowledge of key
facts and incorporation of patient goals and concerns
into the decision.
Development of the Decision Quality Instrument
(BCS-DQI©) followed best practices of survey research
methods [22-24]. We derived the initial set of facts and
goals from a thorough review of the clinical literature
and from focus groups of breast cancer patients. The
candidate facts and goals were then rated by conveni-
ence samples of patients (n = 17) and a multidisciplinary
group of providers (n = 27) to evaluate accuracy, import-
ance and completeness [25,26]. Experts in survey re-
search drafted items to cover the key content and
conducted cognitive interviews with patients (n = 6) in
order to ensure comprehension and acceptability. Of the
patients who participated in cognitive interviews, two
had Stage I disease, 3 had Stage II, and one had un-
known stage. Time since diagnosis ranged from 6 months
to 5 years.
Study design
The instrument was tested in a cross-sectional survey of
breast cancer patients and providers at four National
Cancer Institute-designated cancer centers in 2008,
along with healthy volunteers from one of the sites. The
four cancer centers were academically affiliated and lo-
cated in urban areas in the Northeast, Southeast, and
West Coast of the United States. The study was
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Farber Cancer Institute, Massachusetts General Hospital,
University of California San Francisco, and University of
North Carolina Chapel Hill.
Samples and procedures
Eligible patients were adult women, diagnosed in 2005
or 2006 with early stage breast cancer, as reported in the
cancer registry at each site. Exclusion criteria were a
diagnosis prior to 2005, Stage 3 or higher, ductal carcin-
oma in situ only, bilateral breast cancer, receipt of neo-
adjuvant(before surgery) chemotherapy, and inability to
read or speak English. The patients’ treating physicians
approved contact.
Eligible patients received the study packet, including
an informed consent form, in the mail. Respondents
returned their signed informed consent form, signed
authorization to access the medical record, and com-
pleted study questionnaire by mail. After two weeks, the
study staff called those who did not opt out. After four
weeks, non-respondents received a reminder mailing
and follow up phone call. Respondents received a thank-
you letter and small compensation (e.g., $8 book of
stamps) for completing the survey. A subset of respon-
dents across all sites received a second survey by mail
approximately four weeks after responding, to assess
test-retest reliability of the decision quality instrument.
A multidisciplinary group of breast cancer providers
(medical oncologists, radiation oncologists, surgical on-
cologists, plastic surgeons, and general surgeons) was
identified by the principal investigator at each site.
Healthy volunteers who had no history of breast cancer
and were not clinicians were recruited through employee
email bulletins of Partners Healthcare in Massachusetts.
Providers and healthy volunteer participants received the
knowledge portion of the survey by mail. All potential
participants received an email reminder after two weeks
and a mailed reminder after four weeks. Providers re-
ceived $50 cash or a gift card upon completion of the
survey. Healthy volunteers received a book of stamps
upon completion.
Measures
We collected data on demographics and treatment his-
tory from each site’s cancer registry and the patient’s re-
port on the survey. When patient self-report conflicted
with the registry on a medical or treatment issue (e.g.,
stage of disease), we examined the medical record to re-
solve the issue. The survey included the following
measures:
1. Breast Cancer Systemic Therapy Decision Quality
Instrument (BCS-DQI ©, see Additional file 1).
Items cover decisions about adjuvant chemotherapyand hormone therapy. Here we report on the
chemotherapy items only. Findings regarding the
hormone therapy items will be reported separately.
The instrument has two primary domains:
a. Knowledge: 8 multiple choice and 4 open-ended
items about recurrence, survival, treatment pro-
cesses, and risks associated with chemotherapy.
b. Goals and concerns: 5 items rating on a scale
from 0 (not at all important) to 10 (extremely
important).
2. Decision process: 4 items about the nature of the
interaction with health care providers including
discussion of chemotherapy, pros and cons, and
patients’ preferences. In addition, 1 item asked
patients about who made the final decision about
treatments (mainly the doctor, mainly me, both
equally).
3. Patient’s preferred treatment: A single item asked,
“Which treatment was your personal preference?”
with 4 possible responses: chemotherapy only,
hormone therapy only, both chemotherapy and
hormone therapy, not have chemotherapy and not
have hormone therapy.
4. Treatment received: A single item asking “Did you
have chemotherapy?”
5. Informed: A single item asking “How informed did
you feel about chemotherapy treatments?” with a 0
to 10 rating scale where 0 (not informed at all) and
10 (extremely well informed).
Confidence: A single item asking “How confident were
you that the decision about chemotherapy was the right
one?” with a 0 to 10 rating scale where 0 (not confident
at all) and 10 (extremely confident). This item has been
used in large national studies of decision making. Those
studies found that patients reporting a stronger treat-
ment preference and more involvement in decision mak-
ing had higher confidence [27,28].
6. Regret: A single item asking “If you had to do it
again, would you have the same treatments?” with a
5-point Likert scale. The response options were: def-
initely have the same, probably have the same, not
sure, probably not have the same, and definitely not
have the same. This item has been used in national
studies of decision making that found higher prefer-
ence concordance was associated with lower regret
[29].
Healthy Volunteer survey: Healthy volunteers com-
pleted the knowledge questions and some demographic
items.
Provider survey: Providers completed the knowledge
questions, reported how important each item was
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the knowledge questions covered key content (extremely
well, very well, somewhat well, not at all well). We did
not ask providers to suggest additional knowledge items,
since we had done that in prior stages of instrument de-
velopment [26].
Analysis
Sample evaluation
We began by evaluating demographics and response
rates of the three samples (patient, provider, healthy
volunteer).
Item retention and deletion
We evaluated each item in terms of problems with for-
mat, level of difficulty, redundancy, and floor and ceil-
ing effects. A problem with format was defined as more
than 5% of respondents having a problem, such as
marking two answers when one was expected. A know-
ledge item was identified as possibly too difficult if
fewer than 50% of providers responded correctly, or too
easy if more than 80% of healthy volunteers answered
correctly. An item was identified as possibly redundant
if inter-item correlation was greater than 0.8. A steering
committee composed of six experts in survey research,
decision sciences, and breast cancer care (including two
of the authors KS and CL) reviewed these analyses and
recommended items for revision or deletion.
Knowledge score
A total knowledge score for each patient was calculated,
using the items that were retained after the item retention
and deletion process. The knowledge score was defined
as the percentage of knowledge questions answered cor-
rectly. Missing responses to the knowledge items were
considered incorrect, and any respondent who did not
complete at least half of the knowledge items did not re-
ceive a knowledge score. An aggregate total knowledge
score (0-100%) was computed for each sample.
Concordance score
We limited the concordance analysis to Stage I patients
since chemotherapy has modest absolute impact on their
year survival [3-5], and guidelines recommend consider-
ing (rather than definitely providing) chemotherapy, so
their decisions are more preference-sensitive. The con-
cordance analysis began by examining each goal to deter-
mine whether or not it distinguished between those who
did and did not have chemotherapy. Then we included
the goals, along with age, and hormone receptor status
(defined as estrogen and progesterone receptor positive
or not) in a multivariable logistic regression model, with
receipt of chemotherapy as the dependent variable. To
take into account correlation of observations from thesame hospital, a Generalized Estimating Equations (GEE)
approach was used with study site as a clustering variable.
A patient who had predicted probability ≥0.5 and re-
ceived chemotherapy, or who had predicted probabil-
ity <0.5 and did not receive chemotherapy, was
defined as having care that “matched” her goals. A
summary concordance score (0-100%) was calculated
by dividing the number of patients who matched by
the total number of patients.
In addition to this concordance analysis in all Stage I
patients, we performed an additional analysis in Stage I
patients with hormone receptor-negative tumors, since
guidelines provide stronger recommendations for chemo-
therapy in these patients [1].
Acceptability and feasibility
We examined acceptability using instrument completion
time, response rates, and written comments. We only
had an estimate of completion time because participants
had reported completion time for the whole survey,
which included scales other than the systemic therapy
DQI. We evaluated feasibility using item non-response
patterns. Any item with more than 5% missing responses
was subject to revision.
Assessment of reliability
To examine retest reliability, we calculated the intra-class
correlation coefficient for the total knowledge score and
for the individual goals and concerns. The target was to
exceed 0.7. Because the knowledge items were not based
on a single underlying construct, we did not calculate
Cronbach’s alpha or evaluate internal consistency.
Validity of knowledge score
For discriminant validity of the knowledge items, we
tested the hypothesis that the provider total knowledge
score would be higher than the patient score, and the
patient score would be higher than the healthy volunteer
score (using ANOVA with planned comparison). For
content validity, we evaluated whether or not at least
70% of providers reported that the knowledge items cov-
ered key content.
Validity of concordance score
This analysis was limited to Stage I patients. For con-
struct validity of the concordance model, we tested
whether or not patients who stated a preference for
chemotherapy had a higher model-predicted probability
of chemotherapy than those who were unsure, using a
two-sample t-test. We examined the hypothesis that
concordance would be associated with less regret using
a Chi-squared test. We also tested the hypothesis that
concordance would be associated with more confidence
in decisions using a two-sample t-test. For content
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least 20% of patients included each item in their top
three most important goals.
Results
Sample characteristics
This study was part of a larger study of breast cancer
treatment decisions, in which some patients received the
survey on systemic therapy, and others received a survey
on breast reconstruction. In the overall study, 456 out of
768 patients (59.4%) participated in the initial survey,
and 125/137 (91.2%) in the retest survey. This paper in-
cludes 352 who completed the systemic therapy initial
survey and 89 systemic therapy retest surveys. Many of
those patients (237 of 352, 67.3%) had Stage I disease
and were included in the concordance analyses. AmongTable 1 Characteristics of patients and healthy volunteers
Stage I
All 237 (67.3) 115
Age mean (SD) 57 (11) 57
Race, n (%)
White 199 (84.0) 92
Black 17 (7.2) 13
Hispanic 7 (3.0) 2
Asian, Hawaiian, Pacific Islander 7 (3.0) 4
Other/unknown 7 (3.0) 4
Education, n (%)
HS or less 29 (12.2) 13
Some college 51 (21.5) 36
College or more 157 (66.2) 66
Hormone receptor status, n (%)
Positive 198 (83.5) 96
Negative 39 (16.5) 19
Local treatment, n (%)
Lumpectomy 172 (72.6) 80
Mastectomy 65 (27.4) 35
Systemic therapy, n (%)
Chemotherapy only 33 (13.9) 21
Hormone therapy only 124 (52.3) 22
Both 51 (21.5) 65
No systemic therapy 29 (12.2) 7
Months since diagnosis
Median (25th, 75th) 29 (23,38) 31
Overall Health, n (%)
Excellent/very good 159 (67.1) 70
Other 78 (32.9) 45
Abbreviations: na not applicable; SD standard deviation.the Stage I patients, 35.4% received chemotherapy, alone
or in combination with hormone therapy (Table 1). The
rate of chemotherapy did not vary by site, for Stage I or
Stage II patients. The mean length of time since diagno-
sis was 30.8 months (SD 9.8). The sample of 35 healthy
volunteers was similar to the patient sample, in terms of
race, education, marital status, and reported health status,
but was younger on average (42 vs. 57 years, p <0.001)
(Table 1). Most providers who received the survey com-
pleted it (89 of 116, 77%). The providers’ average age
was 45 years (SD 9), most were female (65%), and they
had been in practice an average of 15 years (SD 11).
The provider sample was multidisciplinary, including
medical oncologists (33%), nurses (29%), surgeons/sur-
gical oncologists(17%), radiation oncologists (8%) and
plastic surgeons (8%).Patients Healthy
volunteersStage II Total
(32.7) 352 (100.0) 35
(12) 57 (11) 42.4 (11)
(80.0) 291 (82.7) 26 (74.3)
(11.3) 30 (8.5) 3 (8.6)
(1.7) 9 (2.6) 1 (2.9)
(3.5) 11 (3.1) 3 (8.6)
(3.5) 11 (3.1) 2 (5.7)
(11.3) 42 (11.9) 0 (0.0)
(31.3) 87 (24.7) 8 (22.9)
(57.4) 223 (63.4) 27 (77.1)
(83.5) 294 (83.5) na
(16.5) 58 (16.5) na
(69.6) 252 (71.6) na
(30.4) 100 (28.4) na
(18.3) 54 (15.3) na
(19.1) 146 (41.5) na
(56.5) 116 (33.0) na
(6.1) 36 (10.2) na
(22,38) 30 (23,38) na
(60.9) 229 (65.1) 32 (91.4)
(39.1) 123 (34.9) 3 (8.6)
Table 2 Selected knowledge items and responses (of 12
total items)
Question and possible
responses (correct response in
italics)*
Number with this response, n (%)
Patients Providers Controls
N 352 89 35
How much would waiting 4 weeks to make a decision about
chemotherapy and hormone therapy affect chances of survival?
A lot 36 (10.2) 0 (0) 6 (17)
Somewhat 54 (15.3) 5 (6) 14 (40)
A little or not at all 215 (61.1) 81 (91) 13 (37)
I am not sure 40 (11.4) 1 (1) 2 (6)
Missing 7 (2.0) 1 (1) 0 (0)
Without chemotherapy or hormone therapy, about how many women
with early stage breast cancer will eventually die of breast cancer?
More than half 52 (14.8) 5 (6) 14 (40)
About half 44 (12.5) 7 (8) 7 (20)
Less than half 105 (29.8) 70 (79) 10 (29)
I am not sure 144 (40.9) 3 (3) 4 (11)
Missing 7 (2.0) 4 (4) 0 (0)
Without chemotherapy or hormone therapy, about how many women
with early stage breast cancer will be cancer free in ten years?
More than half 77 (21.9) 48 (54) 4 (11)
About half 44 (12.5) 15 (17) 3 (9)
Less than half 76 (21.6) 18 (20) 21 (60)
I’m not sure 146 (41.5) 4 (4) 7 (20)
Missing 8 (2.3) 4 (4) 0 (0)
Out of 100 women who have chemotherapy, how many will have a
serious side effect, such as another cancer or serious heart problem?
Fewer than 5 70 (19.9) 59 (66) 5 (14)
5 to 10 63 (17.9) 15 (17) 12 (34)
11 to 20 23 (6.5) 4 (4) 7 (20)
More than 20 18 (5.1) 1 (1) 4 (11)
I am not sure 166 (47.2) 7 (8) 7 (20)
Missing 10 (2.8) 3 (3) 0 (0)
If 100 women with early breast cancer did not have chemotherapy or
hormone therapy, how many would be cancer free in 10 years?
(___ write in number)
Answer less than 60 139 (39.5) 18 (20) 28 (80)
Answer within 60–90 range 79 (22.4) 31 (35) 1 (3)
Answer greater than 90 13 (3.7) 0 (0) 0 (0)
Not sure 115 (32.7) 15 (17) 6 (17)
Missing 6 (1.7) 25 (28) 0 (0)
Total knowledge score, mean (SD) 40 (21.0) 71 (17) 29 (16)
*Some questions have been shortened to fit this table.
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Two knowledge items were deleted for being too easy –
“Can breast cancer come back after chemotherapy?”
(correct answer “yes”) and “Mark whether or not some
women have this side effect from chemotherapy: a. hair
loss” (correct answer“yes”). We also recommended redu-
cing the number of open-ended quantitative estimate
questions (e.g., “If 100 women with breast cancer like
yours had chemotherapy, about how many would be
cancer free in ten years? ___ write in number of people”)
from 4 to 2, because of feedback that patients had diffi-
culty distinguishing among the four recurrence/survival
scenarios, and because the questions did not add more
information. We kept some of the open-ended questions
because they were on critical topics, such as recurrence.
We recommended removal of the response option “I
am not sure” because patients used it so frequently (fre-
quency ranging from 11.4 to 49.4%) (Table 2), and it ap-
peared to result in underestimation of patient knowledge.
Two of the goal items had a ceiling effect. For “Live as
live as long as possible,” 284 of 352 patients (79.5%) rated
the importance as 10 out of 10. For “Lower chance of re-
currence”, 311 of 354 (88.4%) rated the importance as 10
out of 10. We kept these items for the concordance ana-
lyses because most patients included them in their top
three issues. However, the steering committee recom-
mended revision in future versions to improve their ability
to discriminate between patients who had chemotherapy
and those who did not.
At least 20% of patients selected each of the goals, ex-
cept one, in their top three. One goal, “Avoid the costs
of having additional treatments”, was deleted for lack of
content validity – only 5.4% of respondents selected it
in their top three, and its selection did not vary by
treatment. Patients who did not undergo chemotherapy
had a slightly different frequency of selecting goals in
their top three, compared to those who did undergo
chemotherapy. For example, fewer patients who did not
have chemotherapy selected “live as long as possible”
(84.1 for those who did not have chemotherapy versus
92.4% for those who did, p = 0.021) and “lower the
chance of having cancer come back” (85.7% vs. 98.2%,
p = 0.001), in their top three goals.
Acceptability and feasibility
The estimated mean completion time for the DQI (in-
cluding the knowledge items, goals and decision
process items) was 7.2 minutes (range 2.3, 22.9 mi-
nutes). The knowledge items had a mean of 2.5% miss-
ing responses (range 1.4 to 4.5%). Six respondents
(1.7%) did not answer enough knowledge items to gen-
erate a total knowledge score. For the goal items, the
missing responses were also infrequent, with a mean of
2.8% (range 0.4 to 4.4%).Reliability
The total knowledge score had an intra-class correlation
coefficient (ICC) of 0.75.
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0.78. The individual coefficients were as follows: “avoid
serious risks of chemotherapy such as heart problems
and other cancers” ICC = 0.58, “have a treatment that
was convenient to complete” ICC = 0.66, “avoid having
to take medicine for several years” ICC = 0.67, “avoid the
costs of having additional treatments” ICC = 0.69, “live
as long as possible” ICC = 0.69, “lower the chance of
having cancer come back” ICC = 0.78.
Validity of knowledge score
The average patient knowledge score, among the 346
(98.3%) patients who completed at least half of the
knowledge questions, was 40.1 (SD 20.9). The average
provider knowledge score (71.2, SD 17.0) was higher
than the patient score (mean difference 31.1, 95% confi-
dence interval 26.9, 35.3). The average healthy volunteer
knowledge score (28.8, SD 16.0) was lower than the pa-
tient score (mean difference 11.2, 95% confidence inter-
val 5.4, 17.1). Most providers (62%) reported that the
knowledge items covered key content extremely or very
well. An additional 33% reported that the items covered
key content somewhat well. In the written comments,
providers did not note any specific missing content.
Validity of concordance score
These analyses were limited to Stage I patients (n = 232).
On multivariable analysis, none of the patient goals was
meaningfully associated with receipt of chemotherapy.
Age and hormone receptor status were associated with
chemotherapy in the multivariable model, with large odds
ratios (Table 3). On bivariable analysis, several goals were
associated with chemotherapy treatment. For “live as long
as possible”, the mean importance score was 9.87 in pa-
tients who had chemotherapy and 9.64 in patients who
did not (p = 0.008). For “lower the chance of having can-
cer come back”, the mean importance score was 9.93 in
patients who had chemotherapy and 9.77 in those who
did not (p = 0.02). For “avoid serious risks of chemother-
apy such as heart problems and other cancers”, the mean
importance score was 7.01 in patients who had chemo-
therapy and 7.76 in those who did not (p = 0.076).Table 3 Multivariable logistic regression model of characteris
Characteristic
Negative hormone receptor status
Age (increment of 10)
Live as long as possible
Have a treatment that was convenient to complete
Lower the change of having cancer come back
Avoid the costs of having additional treatments
Avoid serious risks of chemotherapyIn the analysis limited to patients with Stage I and hor-
mone receptor positive tumors, no goal was associated
with having chemotherapy. Only age was associated with
chemotherapy (odds ratio 0.478, 95% confidence interval
0.332, 0.687).
With the multivariable model of treatment, which in-
cludes age, hormone receptor status, and goals, 77.6% of
patients had treatment that was concordant with the
model’s prediction (Table 4). Patients who stated a pref-
erence for chemotherapy had higher model-predicted
probability of chemotherapy (0.52), compared to those
who stated a preference for no chemotherapy or were
unsure (0.28, p < 0.0001). Having concordance was not
associated with less decisional regret (11.7% for concord-
ant versus 15.4% for non-concordant, p = 0.48) or with
more confidence in decisions (8.4 for concordant versus
8.2 for non-concordant, p = 0.67).
Decision process
Patients’ reports about their involvement in the decision
process were variable (Table 5). A minority of patients
(42.9%) reported that their doctor asked their preference.
When asked who made the final decision, 45.7% re-
ported “mainly me”, 22.7% reported “mainly the doctor”,
and 29.5% reported “both equally”.
Discussion
The Breast Cancer Systemic Therapy Decision Quality
Instrument is designed to measure the degree to which
patients’ chemotherapy decisions are informed and
concordant with personal goals. The knowledge score
was reliable, and it discriminated among providers, pa-
tients, and healthy volunteers. The goal items had
modest retest reliability and strong content validity.
Patients were able to complete the instrument quickly
with few problems.
Concordance
We were somewhat surprised to find that none of the
patients’ goals was meaningfully associated with treat-
ment in the concordance model. Although one goal
(“Have a treatment that was convenient to complete”)tics associated with chemotherapy in Stage I patients
Odds ratio 95% CI
14.3 5.51, 37.17
0.46 0.36 0.59
1.45 0.78, 2.66
1.03 1.01, 1.04
1.78 0.76, 4.17
1.01 0.94, 1.09
0.93 0.86, 1.01
Table 4 Concordance between predicted and actual
treatment for Stage I patients
Actual chemotherapy treatment Total
Yes No
Predicted chemotherapy treatment, n (%)
Yes, n (%) 43 (18.5) 11 (4.7) 54
No, n (%) 41 (17.7) 137 (59.1) 178
Total*, n (%) 84 148 232
% of the total 232 patients.
*5 patients were not included in the analysis due to missing responses for all
goal items.
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the odds ratio was so close to 1 (1.03) that we did not
consider it clinically meaningful. One clinical factor,
namely hormone receptor status, was the strongest pre-
dictor of receipt of chemotherapy. Hormone receptor
status, as well as other clinical and patient features, such
as age and tumor stage, should, in fact, guide care deci-
sions. Some clinicians might even argue that providers
should recommend chemotherapy to their patients with
hormone receptor negative disease. However, for hor-
mone receptor positive patients, it is reasonable for pa-
tients’ goals to play a role in determining whether or not
to undergo chemotherapy. When we restricted the con-
cordance analyses to stage I, hormone receptor positive
participants, we still found that only age was associated
with receipt of chemotherapy. None of the goals ap-
peared to have any impact on receipt of chemotherapy,Table 5 Decision process by stage
Decision process question*, n (%)
Did any doctor tell you that having or not having chemotherapy was a choic
Yes
No
I am not sure/missing
How much did doctors discuss the reasons to have chemotherapy?
A lot/some
A little/not at all
I am not sure/missing
How much did doctors discuss reasons not to have chemotherapy?
A lot/some
A little/not at all
I am not sure/missing
Did any doctor ask you whether you preferred to have chemotherapy?
Yes
No
I am not sure/missing
Mean decision process score (SD)**
*Questions have been shortened to fit this table.
**Score reflects 1 point for each question answered with yes, a lot, or some (rangeeven for hormone receptor positive patients. One inter-
pretation of these results is that providers use clinical
features to guide treatment choices, with little regard for
patients’ goals and preferences.
Another possible interpretation is that the goal items
in this instrument may not have captured aspects that
were driving patients’ decisions and as a result, the
model may not reflect the tailoring of treatments to pa-
tients’ goals. Also, the responses to the goal items had
little variability, limiting our ability to discriminate
among the treatment options. Although the differences
in the mean responses by treatment were statistically
significant, the actual magnitude of the differences was
quite small and would be difficult to use to guide clinical
decisions. Future studies could explore alternative item
and response formats for eliciting patients’ goals to in-
crease variability.
A limitation of the concordance analysis is that a few
of the Stage I patients may have met guideline criteria
for chemotherapy (Her2 neu positive tumor larger than
1 centimeter, triple negative tumor larger than 1 centi-
meter, or high 21-gene assay score) [1,2]. We did not
collect clinical data at that level of detail, however, so we
could not remove those patients from the concordance
analysis.
Decision process
Our data on the decision process suggest that providers
may not be taking patients’ goals and preferences intoStage I Stage II Total
e for you?
169 (71.3) 80 (69.6) 249 (70.7)
57 (24.1) 30 (26.1) 87 (24.7)
11 (5.1) 5 (4.3) 16 (4.8)
139 (58.6) 97 (84.3) 236 (67.0)
80 (33.8) 13 (11.3) 93 (26.4)
18 (7.6) 5 (4.3) 23 (6.5)
119 (50.2) 44 (38.3) 163 (46.3)
105 (44.3) 61 (53.0) 166 (47.2)
13 (5.5) 10 (8.6) 23 (6.6)
105 (44.3) 46 (40.0) 151 (42.9)
103 (43.5) 56 (48.7) 159 (45.2)
29 (12.6) 13 (11.3) 42 (12.2)
2.2 (1.4) 2.3 (1.2) 2.3 (1.3)
0 to 4).
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their provider asked about their preferences for chemo-
therapy. Discussing patients’ goals and preferences is a
core element of shared decision making and is important
for patient-centered care. Patients and providers may
not be viewing chemotherapy as a preference-sensitive
decision for stage 1 patients, but instead considering it
as effective care. Treatment guidelines, however, clearly
state that use of chemotherapy for most patients with
stage I disease is dependent upon patients’ preferences
[1]. Additional studies may be warranted to understand
factors driving providers’ recommendations for use of
chemotherapy, including financial and organizational in-
centives [30].
Knowledge
The results provide evidence of the reliability and valid-
ity of the knowledge score. Few other validated measures
of knowledge about chemotherapy are available. A 2003
randomized controlled trial of a decision aid about
chemotherapy used a 25-item questionnaire that in-
cluded true-false items about risk of breast cancer recur-
rence and risks and benefits of chemotherapy [31]. The
questionnaire was based on those used in prior studies
of surgery and radiation decisions [32,33], but its psy-
chometric properties have not been reported. Other ad
hoc knowledge measures have focused on the accuracy
of patients’ estimates of their personal risk of breast can-
cer recurrence or their estimate of the survival benefit of
chemotherapy [17-19,34].
Patient knowledge about key facts related to chemo-
therapy was quite low in our population, with average
overall knowledge of 40.1%. Knowledge about the nat-
ural history of early stage breast cancer was particularly
low, with only 32.6% of patients answering correctly.
Most patients who answered incorrectly overestimated
mortality. Knowledge about survival with chemotherapy
was low, with 27% of patients answering correctly. Most
patients who answered incorrectly overestimated the
benefit of chemotherapy on survival.
Prior research suggests that patients tend to overesti-
mate baseline recurrence, mortality rates, and the benefit
of chemotherapy; while providers emphasize relative bene-
fit of chemotherapy in terms of impact on 5 or 10 year re-
currence [10-12]. This relative benefit is often in the range
of 30%, which sounds very high to both patients and pro-
viders. When providers educate patients about the abso-
lute benefit of chemotherapy on ten-year mortality (which
can range from 2-11%), both parties appear to recognize
that the decision is preference-sensitive, and fewer pa-
tients elect chemotherapy [9,10,17].
The study had some important limitations. Patients
were an average of 2.6 years (SD 9.8) out from treat-
ment, so they may have forgotten some information theyknew at the time of decision making. Their responses to
questions about goals may have been subject to recall
bias, with a tendency to favor goals that were more con-
sistent with the treatment they had. The study popula-
tion was primarily white, educated, and higher-income
than average, so the performance of the instrument in
other populations remains unclear. This study was part
of a larger study to validate other breast cancer decision
quality measures, and the overall response rate for the
larger study was lower among non-white patients [35].
We conducted the study at four academic comprehen-
sive cancer centers, where select patients may be re-
ferred, and practice styles may differ from that in the
community, which may further limit the generalizability
of our findings. Healthy volunteers were from one of the
sites, so their responses to the knowledge questions may
not be representative of healthy persons from other
locations.
Conclusions
The Breast Cancer Systemic Therapy Decision Quality
Instrument demonstrated strong reliability and validity
as a measure of patient knowledge about chemotherapy
for early stage breast cancer in this sample, but its ability
to measure concordance was limited. In this population,
no patient goal was associated with treatment, and most
patients reported they were not asked their preference,
suggesting that patients’ goals may not have been ad-
equately considered in treatment decision making about
chemotherapy. Further testing will be important to
understand the performance of the survey in newly diag-
nosed patients who are actively making the decision, to
evaluate alternative approaches to eliciting patients’
goals, to examine the responsiveness of the knowledge
score to interventions, such as patient decision aids, and
to gather data to help set benchmarks for knowledge
and concordance scores.
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